SB1317: Phase I started

Tragara began an open-label, dose-ranging, U.S. Phase I trial to evaluate oral TG02. Tragara has exclusive, worldwide rights from S*BIO to develop and commercialize TG02 (see BioCentury, Jan. 26, 2009...